Pharsight

Drugs that contain Deferasirox

1. Jadenu patents expiration

JADENU's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 23, 2023

Market Authorisation Date: 30 March, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents